Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Operations (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Cash from Operations for 11 consecutive years, with 14710000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 62.17% to 14710000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1117000.0 through Dec 2025, up 100.75% year-over-year, with the annual reading at 1117000.0 for FY2025, 100.75% up from the prior year.
  • Cash from Operations hit 14710000.0 in Q4 2025 for Seres Therapeutics, down from 2206000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 127742000.0 in Q3 2021 to a low of 76584000.0 in Q1 2023.
  • Historically, Cash from Operations has averaged 24348700.0 across 5 years, with a median of 39288500.0 in 2021.
  • Biggest YoY gain for Cash from Operations was 593.86% in 2021; the steepest drop was 189.3% in 2021.
  • Year by year, Cash from Operations stood at 51863000.0 in 2021, then fell by 1.98% to 52892000.0 in 2022, then grew by 10.2% to 47499000.0 in 2023, then grew by 18.14% to 38882000.0 in 2024, then soared by 62.17% to 14710000.0 in 2025.
  • Business Quant data shows Cash from Operations for MCRB at 14710000.0 in Q4 2025, 2206000.0 in Q3 2025, and 13289000.0 in Q2 2025.